Q-omics provides the consensus-scored MT1CP profile across patient tissues and cancer cell-line models. MT1CP expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MT1CP is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, MT1CP RNA expression shows 5,114 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight THYM, COAD, and KIRC as cancer lineages where MT1CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1CP survival associations across molecular data types. MT1CP RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1CP RNA expression–survival associations across cancer types. High MT1CP expression shows unfavorable associations in THYM, HNSC, ACC, DLBC, CESC and ESCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MT1CP RNA expression.
This table summarizes MT1CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MT1CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1CP shows lower tumor expression in COAD, LIHC, THCA, CHOL, KICH and BRCA. The COAD box plot shows higher MT1CP RNA expression in normal versus tumor tissue (log2 FC = −2.065, t-test p < 0.001).
This table shows molecular features associated with MT1CP in patient tissues and cancer cell lines. In patient samples, MT1CP shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
